Chelsea McGowen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chelsea McGowen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Angela M. Stover
Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
3 shared publications - Bradford E. Jackson
University of North Carolina at Chapel Hill 2 Chapel Hill
3 shared publications - Casey L. Daniel
University of South Alabama, College of Medicine at Mobile, Alabama
3 shared publications - Chao-Hui Sylvia Huang
Center for Palliative and Supportive Care, University of Alabama at Birmingham , Birmingham, AL
3 shared publications - Courtney Andrews
University of Alabama at Birmingham, Birmingham, AL
3 shared publications - Doris Howell
Princess Margaret Cancer Research Institute, Toronto, ON M5G 2M9, Canada
3 shared publications
Latest Publications
- 1 November 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (11_suppl) , 345
Symptom trajectory for patients utilizing remote symptom monitoring during gastrointestinal cancer treatment.
345 Background: Use of electronic patient-reported outcome data allows patients to report symptoms in real time. This analysis aims to better understand the trajectory for symptoms reported via Remote Symptom Monitoring (RSM) by patients receiving gastrointestinal (GI) cancer treatment. Methods: This retrospective cohort study included patients initiating GI cancer treatment (chemotherapy, targeted therapy, and immunotherapy) between August 2022 and April 2023 at USA Health Mitchell Cancer Institute (MCI). Patients were eligible if they were starting a new treatment or had started treatment in the past 30 days. Patients received a weekly symptom survey over the course of 24 weeks through text message or e-mail. Patients were monitored for a total of 24 weeks regardless of their enrollment date. Patients reported symptoms as mild, moderate, severe, or very severe. All moderate and severe alerts were sent to the clinical nurse via the electronic medical record (EMR) to be acknowledged. After enrollment, health information including age, race, sex, zip code, ethnicity, cancer type, and cancer stage were extracted from the EMR. Descriptive statistics were calculated to examine frequencies of reported symptoms and their severity over time. Results: Of 75 GI patients approached, 63 patients (84%) were enrolled in RSM; 44% were female; 30% of patients were Black or African American, and median age was 65 (range 30-82). GI cancer types varied; Pancreatic (21%), Rectal (13%), Colorectal (14%), Colon (13%), Gastric (11%), Liver (11%), and other (17%). Over 24 weeks, 424 alerts were reported. Pain (31%), nausea and vomiting (21%), and decreased appetite (17%) were the most reported symptoms. 311 alerts were moderate (73%) and 113 were severe (27%). At week 0 (baseline; n = 63) 37 moderate alerts and 21 severe alerts were reported. At week 24 (final week; n = 63) 7 moderate alerts and 6 severe alerts were reported. Overall, there was a decreasing trajectory from week to week for moderate and severe alerts, with outliers noted at weeks 8 and 20. Conclusions: Findings suggest that RSM allows for an improvement in symptom trajectory for GI cancer patients based on the decrease in moderate and severe alerts reported from baseline to week 24. This decrease suggests that reported symptoms are being appropriately monitored and addressed by the patient's clinical care team due to improvement of symptoms or improvement of symptom management. Future research is needed to determine the benefits of prolonged RSM utilization by patient-reported quality of life as well as survival rate.
- 1 November 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (11_suppl) , 345
Symptom trajectory for patients utilizing remote symptom monitoring during gastrointestinal cancer treatment.
345 Background: Use of electronic patient-reported outcome data allows patients to report symptoms in real time. This analysis aims to better understand the trajectory for symptoms reported via Remote Symptom Monitoring (RSM) by patients receiving gastrointestinal (GI) cancer treatment. Methods: This retrospective cohort study included patients initiating GI cancer treatment (chemotherapy, targeted therapy, and immunotherapy) between August 2022 and April 2023 at USA Health Mitchell Cancer Institute (MCI). Patients were eligible if they were starting a new treatment or had started treatment in the past 30 days. Patients received a weekly symptom survey over the course of 24 weeks through text message or e-mail. Patients were monitored for a total of 24 weeks regardless of their enrollment date. Patients reported symptoms as mild, moderate, severe, or very severe. All moderate and severe alerts were sent to the clinical nurse via the electronic medical record (EMR) to be acknowledged. After enrollment, health information including age, race, sex, zip code, ethnicity, cancer type, and cancer stage were extracted from the EMR. Descriptive statistics were calculated to examine frequencies of reported symptoms and their severity over time. Results: Of 75 GI patients approached, 63 patients (84%) were enrolled in RSM; 44% were female; 30% of patients were Black or African American, and median age was 65 (range 30-82). GI cancer types varied; Pancreatic (21%), Rectal (13%), Colorectal (14%), Colon (13%), Gastric (11%), Liver (11%), and other (17%). Over 24 weeks, 424 alerts were reported. Pain (31%), nausea and vomiting (21%), and decreased appetite (17%) were the most reported symptoms. 311 alerts were moderate (73%) and 113 were severe (27%). At week 0 (baseline; n = 63) 37 moderate alerts and 21 severe alerts were reported. At week 24 (final week; n = 63) 7 moderate alerts and 6 severe alerts were reported. Overall, there was a decreasing trajectory from week to week for moderate and severe alerts, with outliers noted at weeks 8 and 20. Conclusions: Findings suggest that RSM allows for an improvement in symptom trajectory for GI cancer patients based on the decrease in moderate and severe alerts reported from baseline to week 24. This decrease suggests that reported symptoms are being appropriately monitored and addressed by the patient's clinical care team due to improvement of symptoms or improvement of symptom management. Future research is needed to determine the benefits of prolonged RSM utilization by patient-reported quality of life as well as survival rate.
- 1 November 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (11_suppl) , 340
Symptom alert by type and severity among cancer patients using electronic patient reported outcomes for remote symptom monitoring.
340 Background: Remote symptom monitoring (RSM) by electronic patient-reported outcomes (ePRO) data can elicit actionable symptoms from patients with cancer. However, patients with different cancer diagnoses are likely to have differing symptom profiles and variability in symptom alerts. To understand potential workflow needs, this analysis was conducted to determine which types of symptoms and severity of alerts can be expected based on cancer type. Methods: Cancer patients initiating chemotherapy, immunotherapy, or targeted therapy at 2 academic cancer centers in Alabama, UAB O’Neal Comprehensive Cancer Center and USA Health Mitchell Cancer Institute (MCI), were enrolled in ePRO-based RSM. Site rollouts were differential: UAB enrolled by disease group starting May 2021, MCI by provider starting July 2021. Patients received weekly symptom surveys of selected PRO-CTCAE questions through the Carevive ePRO mobile platform (PROmpt), triggering alerts to clinical teams if reported symptoms were determined to be moderate or severe. Demographics, cancer diagnosis, and ePRO data were extracted from electronic health records and Carevive. Descriptive statistics of categorical variables were calculated by frequencies and percentages; Cramer’s V and Cohen’s d were used for associations and effect size. Results: UAB enrolled 598 patients and MCI enrolled 274 patients by April 2023, consistent with the patient volume difference of the centers. 68% of enrollees were White; MCI saw a moderately higher % of Black patients (V: 0.21). 67% of enrolled patients were female. Median age was 61 years (Interquartile range: 51-69); UAB patients were slightly younger (d: 0.15). Among 872 enrolled patients, 9765 symptom alerts were generated. There was a small effect of cancer type on the overall type of symptoms and symptom severity reported (V: 0.11 and 0.09 respectively). Of the total number of symptom alerts, 28.0% of the alerts generated were for pain, followed by nausea/vomiting (14.9%), and constipation (11.7%). When broken down by cancer type, pain was the symptom most frequently reported for each type. The next most frequently reported symptoms differed but were as expected by cancer type: coughing/dyspnea by lung cancer patients (20.6%); urinary complaints in genitourinary cancers (14.1%); and nausea/vomiting in gastrointestinal cancers (18.0%). The frequency of moderate alerts was 62.1%, varying from 34.0% in sarcoma to 66.6% in gastrointestinal cancers. 31.1% of the alerts were severe; sarcoma had the most severe alerts (56.0%) and hematologic had the least (27.1%). Conclusions: Across patients with differing cancer types, pain and gastrointestinal issues were over half the reported symptoms. However, variability by cancer diagnosis in both symptom type and severity was observed, suggesting the remote symptom management workload for providers may vary by cancer type.
- 1 November 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (11_suppl) , 340
Symptom alert by type and severity among cancer patients using electronic patient reported outcomes for remote symptom monitoring.
340 Background: Remote symptom monitoring (RSM) by electronic patient-reported outcomes (ePRO) data can elicit actionable symptoms from patients with cancer. However, patients with different cancer diagnoses are likely to have differing symptom profiles and variability in symptom alerts. To understand potential workflow needs, this analysis was conducted to determine which types of symptoms and severity of alerts can be expected based on cancer type. Methods: Cancer patients initiating chemotherapy, immunotherapy, or targeted therapy at 2 academic cancer centers in Alabama, UAB O’Neal Comprehensive Cancer Center and USA Health Mitchell Cancer Institute (MCI), were enrolled in ePRO-based RSM. Site rollouts were differential: UAB enrolled by disease group starting May 2021, MCI by provider starting July 2021. Patients received weekly symptom surveys of selected PRO-CTCAE questions through the Carevive ePRO mobile platform (PROmpt), triggering alerts to clinical teams if reported symptoms were determined to be moderate or severe. Demographics, cancer diagnosis, and ePRO data were extracted from electronic health records and Carevive. Descriptive statistics of categorical variables were calculated by frequencies and percentages; Cramer’s V and Cohen’s d were used for associations and effect size. Results: UAB enrolled 598 patients and MCI enrolled 274 patients by April 2023, consistent with the patient volume difference of the centers. 68% of enrollees were White; MCI saw a moderately higher % of Black patients (V: 0.21). 67% of enrolled patients were female. Median age was 61 years (Interquartile range: 51-69); UAB patients were slightly younger (d: 0.15). Among 872 enrolled patients, 9765 symptom alerts were generated. There was a small effect of cancer type on the overall type of symptoms and symptom severity reported (V: 0.11 and 0.09 respectively). Of the total number of symptom alerts, 28.0% of the alerts generated were for pain, followed by nausea/vomiting (14.9%), and constipation (11.7%). When broken down by cancer type, pain was the symptom most frequently reported for each type. The next most frequently reported symptoms differed but were as expected by cancer type: coughing/dyspnea by lung cancer patients (20.6%); urinary complaints in genitourinary cancers (14.1%); and nausea/vomiting in gastrointestinal cancers (18.0%). The frequency of moderate alerts was 62.1%, varying from 34.0% in sarcoma to 66.6% in gastrointestinal cancers. 31.1% of the alerts were severe; sarcoma had the most severe alerts (56.0%) and hematologic had the least (27.1%). Conclusions: Across patients with differing cancer types, pain and gastrointestinal issues were over half the reported symptoms. However, variability by cancer diagnosis in both symptom type and severity was observed, suggesting the remote symptom management workload for providers may vary by cancer type.
- 1 December 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (12) , e1943-e1952
Adaptation of Remote Symptom Monitoring Using Electronic Patient-Reported Outcomes for Implementation in Real-World Settings
PURPOSE: Despite evidence of clinical benefits, widespread implementation of remote symptom monitoring has been limited. We describe a process of adapting a remote symptom monitoring intervention developed in a research setting to a real-world clinical setting at two cancer centers. METHODS: This formative evaluation assessed core components and adaptations to improve acceptability and fit of remote symptom monitoring using Stirman's Framework for Modifications and Adaptations. Implementation outcomes were evaluated in pilot studies at the two cancer centers testing technology (phase I) and workflow (phase II and III) using electronic health data; qualitative evaluation with semistructured interviews of clinical team members; and capture of field notes from clinical teams and administrators regarding barriers and recommended adaptations for future implementation. RESULTS: Core components of remote symptom monitoring included electronic delivery of surveys with actionable symptoms, patient education on the intervention, a system to monitor survey compliance in real time, the capacity to generate alerts, training nurses to manage alerts, and identification of personnel responsible for managing symptoms. In the pilot studies, while most patients completed > 50% of expected surveys, adaptations were identified to address barriers related to workflow challenges, patient and clinician access to technology, digital health literacy, survey fatigue, alert fatigue, and data visibility. CONCLUSION: Using an implementation science approach, we facilitated adaptation of remote symptom monitoring interventions from the research setting to clinical practice and identified key areas to promote effective uptake and sustainability.
- 1 December 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (12) , e1943-e1952
Adaptation of Remote Symptom Monitoring Using Electronic Patient-Reported Outcomes for Implementation in Real-World Settings
PURPOSE: Despite evidence of clinical benefits, widespread implementation of remote symptom monitoring has been limited. We describe a process of adapting a remote symptom monitoring intervention developed in a research setting to a real-world clinical setting at two cancer centers. METHODS: This formative evaluation assessed core components and adaptations to improve acceptability and fit of remote symptom monitoring using Stirman's Framework for Modifications and Adaptations. Implementation outcomes were evaluated in pilot studies at the two cancer centers testing technology (phase I) and workflow (phase II and III) using electronic health data; qualitative evaluation with semistructured interviews of clinical team members; and capture of field notes from clinical teams and administrators regarding barriers and recommended adaptations for future implementation. RESULTS: Core components of remote symptom monitoring included electronic delivery of surveys with actionable symptoms, patient education on the intervention, a system to monitor survey compliance in real time, the capacity to generate alerts, training nurses to manage alerts, and identification of personnel responsible for managing symptoms. In the pilot studies, while most patients completed > 50% of expected surveys, adaptations were identified to address barriers related to workflow challenges, patient and clinician access to technology, digital health literacy, survey fatigue, alert fatigue, and data visibility. CONCLUSION: Using an implementation science approach, we facilitated adaptation of remote symptom monitoring interventions from the research setting to clinical practice and identified key areas to promote effective uptake and sustainability.
- 16 December 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (4) , 1033-1043
Factors associated with HPV vaccination initiation among United States college students
Human papillomavirus (HPV) remains the most common sexually transmitted infection (STI) in the U.S. despite widespread availability of a safe, effective vaccine. Although young adults are at greatest risk of HPV infection, extensive vaccine promotion and intervention efforts has been directed toward 11–12-year-olds. College students represent an ideal audience for HPV vaccine “catch-up;” however, research indicates inconsistent HPV vaccination rates within this demographic. An online survey assessing HPV and HPV vaccine knowledge and behaviors was distributed to all undergraduate college students at a large, public university in the Deep South region of the U.S. The primary outcome was receipt of HPV vaccination (binary response options of Yes/No). Logistic regression analyses were performed to determine predictors of HPV vaccination. Of the 1,725 who completed the survey, 47.0% reported having received at least one dose of HPV vaccine; overall series completion (series = 3 doses for this population) was 17.4%. The primary outcome was HPV initiation among college students, defined as having received at least one dose of the HPV vaccine. Results indicated substantial gaps in participants’ knowledge of their vaccination status. Provider and parental recommendations as well as social influences were shown to significantly impact student vaccination status, emphasizing the importance of incorporating these elements in future interventions, potentially as multi-level strategies. Future college interventions should address HPV and vaccination knowledge and the importance of provider and parental recommendations.
- 16 December 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (4) , 1033-1043
Factors associated with HPV vaccination initiation among United States college students
Human papillomavirus (HPV) remains the most common sexually transmitted infection (STI) in the U.S. despite widespread availability of a safe, effective vaccine. Although young adults are at greatest risk of HPV infection, extensive vaccine promotion and intervention efforts has been directed toward 11–12-year-olds. College students represent an ideal audience for HPV vaccine “catch-up;” however, research indicates inconsistent HPV vaccination rates within this demographic. An online survey assessing HPV and HPV vaccine knowledge and behaviors was distributed to all undergraduate college students at a large, public university in the Deep South region of the U.S. The primary outcome was receipt of HPV vaccination (binary response options of Yes/No). Logistic regression analyses were performed to determine predictors of HPV vaccination. Of the 1,725 who completed the survey, 47.0% reported having received at least one dose of HPV vaccine; overall series completion (series = 3 doses for this population) was 17.4%. The primary outcome was HPV initiation among college students, defined as having received at least one dose of the HPV vaccine. Results indicated substantial gaps in participants’ knowledge of their vaccination status. Provider and parental recommendations as well as social influences were shown to significantly impact student vaccination status, emphasizing the importance of incorporating these elements in future interventions, potentially as multi-level strategies. Future college interventions should address HPV and vaccination knowledge and the importance of provider and parental recommendations.